Cite
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.
MLA
Cottu, Paul H., et al. “Phase I Study of Onapristone, a Type I Antiprogestin, in Female Patients with Previously Treated Recurrent or Metastatic Progesterone Receptor-Expressing Cancers.” PLoS ONE, vol. 13, no. 10, Oct. 2018, pp. 1–16. EBSCOhost, https://doi.org/10.1371/journal.pone.0204973.
APA
Cottu, P. H., Bonneterre, J., Varga, A., Campone, M., Leary, A., Floquet, A., Berton-Rigaud, D., Sablin, M.-P., Lesoin, A., Rezai, K., Lokiec, F. M., Lhomme, C., Bosq, J., Bexon, A. S., Gilles, E. M., Proniuk, S., Dieras, V., Jackson, D. M., Zukiwski, A., & Italiano, A. (2018). Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. PLoS ONE, 13(10), 1–16. https://doi.org/10.1371/journal.pone.0204973
Chicago
Cottu, Paul H., Jacques Bonneterre, Andrea Varga, Mario Campone, Alexandra Leary, Anne Floquet, Dominique Berton-Rigaud, et al. 2018. “Phase I Study of Onapristone, a Type I Antiprogestin, in Female Patients with Previously Treated Recurrent or Metastatic Progesterone Receptor-Expressing Cancers.” PLoS ONE 13 (10): 1–16. doi:10.1371/journal.pone.0204973.